Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236827 | 1.00 | HPGD (0.68) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL29760295 | 1.00 | HPGD (0.68) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL21771179 | 0.88 | HPGD (0.62) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL2644150 | 0.84 | KDM4E (0.66) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL22036370 | 0.84 | HPGD (0.59) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL19828935 | 0.84 | HPGD (0.58) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL30296389 | 0.84 | KDM4E (0.66) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL28326301 | 0.84 | L3MBTL1 (0.58) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL18828359 | 0.80 | HPGD (0.56) | HPGDLMNAALDH1A1PKMMEN1 | |
| SCHEMBL9188836 | 0.80 | L3MBTL1 (0.61) | HPGDLMNAALDH1A1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437128-B | Synthetic method of 3-thioether-based isoindolinone compound | 齐鲁工业大学 | 2022-07-12 | — | — | CN | claimed |
| CN-110437128-A | A kind of synthetic method of 3- thioether group isoindoline ketone compound | UNIV QILU TECHNOLOGY | 2019-11-12 | — | — | CN | claimed |
| CN-110437129-A | A kind of straightforward procedure synthesizing 3- ether isoindoline ketone compound | UNIV QILU TECHNOLOGY | 2019-11-12 | — | — | CN | claimed |
| CN-110437129-B | Simple method for synthesizing 3-ether-based isoindolinone compound | 齐鲁工业大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2020-11-12 | — | — | US | disclosed |
| CN-110437128-A | A kind of synthetic method of 3- thioether group isoindoline ketone compound | UNIV QILU TECHNOLOGY | 2019-11-12 | — | — | CN | disclosed |
| CN-110437128-A | A kind of synthetic method of 3- thioether group isoindoline ketone compound | UNIV QILU TECHNOLOGY | 2019-11-12 | — | — | CN | disclosed |
| CN-110437129-A | A kind of straightforward procedure synthesizing 3- ether isoindoline ketone compound | UNIV QILU TECHNOLOGY | 2019-11-12 | — | — | CN | disclosed |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-04-26 | — | — | US | disclosed |
| US-9592497-B2 | Process for the asymmetric hydrogenation of imides | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2017-03-14 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1528923-B1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1528923-A1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003101450-A1 | N- ((3-OXO2, 3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYL) GUANIDINE DERIVATIVES AS NHE-1 INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | HPGD 101/4885LMNA 833/4885ALDH1A1 243/4885 |
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HPGD 4356/4885LMNA 3082/4885ALDH1A1 4002/4885 |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | HPGD 723/4885LMNA 4661/4885ALDH1A1 1644/4885 |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HPGD 4356/4885LMNA 3082/4885ALDH1A1 4002/4885 |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HPGD 4356/4885LMNA 3082/4885ALDH1A1 4002/4885 |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | HPGD 101/4885LMNA 894/4885ALDH1A1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.